Canatu Oyj A Ord (CNTPF) Q2 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

My name is Mari Makkonen and I'm responsible for investor relations. Today, our CEO Juha Kokkonen will start with the first half highlights. Then our CFO Mikko Vesterinen will continue with key financials. And after that, our business unit lead Nedal Safvat will provide an update on medical diagnostics. Finally, Juha will discuss outlook and targets. At the end, we'll have plenty of time for Q&A. You can type in your questions in the event chat at any time. With that, let me hand over to Juha. Thank you, Mari, and welcome also on my behalf. I will go straight to the key messages. We are envisioning here and seeing very rapid growth in artificial intelligence. And that is demanding, creating demand for advanced chips. In terms of the volumes, but in terms of the performance as well. Performance is needed to make these language modelings faster, as well as making it more cost-efficient manner, as well as making it less energy consuming. This development is a main driver for advanced chips that are all the time more and more advanced. And this is driving also demand for CNT pellicles. And CNT pellicles is a small essential part of this development. From the operational progress perspective, the major milestone during the first half of this year was that our first CNT reactor was customer approved. And it is now ready for mass production of CNT pellicle membranes. In addition to that one, we are negotiating new orders in the semiconductor industry with our existing customers. As you do remember, we have two reactor customers there. And in addition to that one, prospective new customers. and we have a project going on there as well. And this will enable that our position across the existing ecosystem remains strong, but we even say that it has improved compared to time of...